Intellia Therapeutics Inc. (NASDAQ:NTLA) went up by 7.39% from its latest closing price compared to the recent 1-year high of $104.87. The company’s stock price has collected 3.99% of gains in the last five trading sessions. The Wall Street Journal reported on 09/16/22 that Crispr Gene-Editing Drugs Show Promise in Preliminary Study
Is It Worth Investing in Intellia Therapeutics Inc. (NASDAQ :NTLA) Right Now?
Plus, the 36-month beta value for NTLA is at 1.85. Opinions of the stock are interesting as 20 analysts out of 28 who provided ratings for Intellia Therapeutics Inc. declared the stock was a “buy,” while 3 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $106.16, which is $63.09 above the current price. NTLA currently public float of 75.75M and currently shorts hold a 8.76% ratio of that float. Today, the average trading volume of NTLA was 1.15M shares.
NTLA’s Market Performance
NTLA stocks went up by 3.99% for the week, with a monthly jump of 6.41% and a quarterly performance of -23.28%, while its annual performance rate touched -52.74%. The volatility ratio for the week stands at 7.59% while the volatility levels for the past 30 days are set at 6.07% for Intellia Therapeutics Inc. The simple moving average for the period of the last 20 days is 6.69% for NTLA stocks with a simple moving average of -25.95% for the last 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Citigroup repeating the rating for NTLA by listing it as a “Neutral.” The predicted price for NTLA in the upcoming period, according to Citigroup is $39 based on the research report published on January 24th of the current year 2023.
Morgan Stanley gave a rating of “Overweight” to NTLA, setting the target price at $84 in the report published on October 11th of the previous year.
NTLA Trading at -6.71% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.26% of loss for the given period.
Volatility was left at 6.07%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares surge +6.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.23% lower at present.
During the last 5 trading sessions, NTLA rose by +3.99%, which changed the moving average for the period of 200-days by -42.96% in comparison to the 20-day moving average, which settled at $36.24. In addition, Intellia Therapeutics Inc. saw 10.43% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NTLA starting from Sepp-Lorenzino Laura, who sale 2,330 shares at the price of $38.48 back on Jan 05. After this action, Sepp-Lorenzino Laura now owns 17,629 shares of Intellia Therapeutics Inc., valued at $89,659 using the latest closing price.
BASTA JAMES, the EVP, General Counsel of Intellia Therapeutics Inc., sale 1,138 shares at $37.21 during a trade that took place back on Jan 04, which means that BASTA JAMES is holding 19,559 shares at $42,345 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -810.37 for the present operating margin
- +79.15 for the gross margin
The net margin for Intellia Therapeutics Inc. stands at -810.49. Equity return is now at value -47.80, with -37.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.